• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

    32.61 -0.30 (-0.91%)
    Streaming Delayed Price Updated: 11:10 AM EDT, Jun 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Teva Pharmaceutical Industries Limited American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    News headline image
    Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
    Driving revenue growth and earnings growth are two different things. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings ↗
    Via Chartmill
    News headline image
    Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
    From Alvotech
    Via GlobeNewswire
    News headline image
    Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
    From Alvotech
    Via GlobeNewswire
    News headline image
    Teva to Present at the Goldman Sachs Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks ↗
    Teva's transformation is gaining momentum. 
    Via The Motley Fool
    News headline image
    The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More. ↗
    The market's rediscovery of Teva Pharmaceuticals remains ongoing. 
    Via The Motley Fool
    News headline image
    Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. ↗
    Teva's turnaround is real -- and may not be over. 
    Via The Motley Fool
    News headline image
    Teva to Present at the BofA Securities Health Care Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗
    A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past. 
    Via The Motley Fool
    News headline image
    Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock. ↗
    That's when its first-quarter results will be published. 
    Via The Motley Fool
    News headline image
    3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
    This once-beaten-down pharma stock remains an intriguing turnaround story. 
    Via The Motley Fool
    News headline image
    Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
    Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities 
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
    Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can... 
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
    In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF... 
    Via MarketMinute
    Topics ETFs Intellectual Property Stocks
    News headline image
    Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
    The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
    March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of... 
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗
    Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.